Summary

  • The authors concluded that daratumumab monotherapy is an effective and well tolerated treatment option in heavily pretreated and refractory patients with multiple myeloma
  • The overall response rate was 29% (95% CI, 21-39)
  • Efficacy was consistent across all subgroups
  • Responses were rapid, durable, and deepened over time
    • 3 sCR; 10 VGPR
    • Depth of response may translate to prolonged overall survival
  • Daratumumab was well tolerated
    • No patients discontinued treatment due to AEs related to daratumumab
  • IRRs predominantly occurred during the first infusion, were usually Grade 1 or 2, and manageable
  • No drug-related AEs led to treatment discontinuation
Prev
Next